

CLAIMS

1. A compound of formula (I)




(I)


or a pharmaceutically acceptable salt thereof, wherein:




is selected from:



i)




, ii)



, and iii) ;

R^1 is selected from hydrogen, C_1-C_6-alkyl, hydroxy-C_1-C_6-alkyl-NH-C(O)-, and a group



; and R^{1a} is hydrogen; or

R^1 and R^{1a}, taken together with the carbon atoms to which they are attached, form a C_3-C_{10}-cycloalkyl;

R^{1b} is selected from hydrogen, halogen, hydroxy, oxo, C_1-C_6-alkyl, and C_1-C_6-alkoxy;

R^{1c} is selected from hydrogen, hydroxy, and oxo;

R^2 is C_1-C_6-alkyl;

R^3 is chloro or bromo;

R^4 is selected from halogen, C_1-C_6-alkyl, halo-C_1-C_6-alkyl, and C_3-C_{10}-cycloalkyl;


R^5 is halogen;

L is selected from a covalent bond, carbonyl, -C(O)NH-,-NHC(O)-, -CH_2NHC(O)-; and

A is selected from 3-14-membered heterocycloalkyl and C_3-C_{10}-cycloalkyl.

2. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

R^1 is selected from C_1-C_6-alkyl, hydroxy-C_1-C_6-alkyl-NH-C(O)-, and a group




; and R^{1a} is hydrogen; or

R^1 and R^{1a}, taken together with the carbon atoms to which they are attached, form a C_3-C_{10}-cycloalkyl; and

R^{1b}, R^{1c}, A, and L are as defined in claim 1.

3. The compound of formula (I) according to claim 2, or a pharmaceutically acceptable salt thereof, wherein

R^1 is selected from C_1-C_6-alkyl, hydroxy-C_1-C_6-alkyl-NH-C(O)-, and a group



;


R^{1b} is C_1-C_6-alkyl;

R^{1c} is hydroxy;

L is carbonyl; and

A is a 3-14-membered heterocycle.

4. The compound of formula (I) according to claim 3, or a pharmaceutically acceptable salt thereof, wherein

R^1 is selected from 2-hydroxyethyl-NH-C(O)-, 2-hydroxypropyl-NH-C(O)-, methyl, and a group 

;

R^{1b} is methyl;

R^{1c} is hydroxy;

L is carbonyl; and

A is a azetidinyl.

5. The compound of formula (I) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^2 is methyl.

6. The compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R^3 is chloro.


7. The compound of formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R^4 is haloalkyl.

8. The compound of formula (I) according to claim 7, or a pharmaceutically acceptable salt thereof, wherein R^4 is CF_3.

9. The compound of formula (I) according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R^5 is fluoro.

10. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from C_1-C_6-alkyl, hydroxy-C_1-C_6-alkyl-NH-C(O)-, and a group



;

R^{1b} is C_1-C_6-alkyl;

R^{1c} is hydroxy;

R^2 is C_1-C_6-alkyl;

R^3 is chloro;


R^4 is halo-C_1-C_6-alkyl;

R^5 is halogen;

L is carbonyl; and

A is a 3-14-membered heterocycle.

11. The compound of formula (I) according to claim 10, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from methyl, 2-hydroxyethyl-NH-C(O)-, 2-hydroxypropyl-NH-C(O)-, and a group 

;

R^{1b} is methyl;

R^{1c} is hydroxy;

R^2 is methyl;

R^3 is chloro;

R^4 is CF_3;

R^5 is fluoro;

L is carbonyl; and

A is azetidinyl.

12. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is selected from:

(7*S*)-11,12-dichloro-9-(2,6-difluorophenyl)-3,7-dimethyl-2,4,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene;

(7*S*)-11-chloro-12-cyclopropyl-9-(2,6-difluorophenyl)-3,7-dimethyl-2,4,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-3,7,12-trimethyl-2,4,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-3,7-dimethyl-12-(trifluoromethyl)-2,4,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene;

azetidin-1-yl-[(7*S*)-11-chloro-9-(2,6-difluorophenyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaen-4-yl]methanone;

[(7*S*)-11-chloro-9-(2,6-difluorophenyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaen-4-yl]-(3-fluoroazetidin-1-yl)methanone;

[(7*S*)-11-chloro-9-(2,6-difluorophenyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaen-4-yl]-(3-hydroxyazetidin-1-yl)methanone;

[(7*S*)-11-chloro-9-(2,6-difluorophenyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaen-4-yl]-(3-methoxyazetidin-1-yl)methanone;

[(7*S*)-11-chloro-9-(2,6-difluorophenyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaen-4-yl]-(3-hydroxy-3-methyl-azetidin-1-yl)methanone;

[(7*S*)-11-chloro-9-(2,6-difluorophenyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaen-4-yl]-(1,1-dioxo-1,4-thiazinan-4-yl)methanone;

N-[(7*S*)-11-chloro-9-(2,6-difluorophenyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaen-4-yl]oxetane-3-carboxamide;

1-[(7*S*)-11-chloro-9-(2,6-difluorophenyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaen-4-yl]pyrrolidin-2-one;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-*N*-[(2*S*)-2-hydroxypropyl]-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene-4-carboxamide;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-*N*-(2-hydroxyethyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene-4-carboxamide;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-*N*-[(2*R*)-2-hydroxypropyl]-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene-4-carboxamide;

(7*S*)-11-chloro-9-(2-chloro-6-fluoro-phenyl)-3,7-dimethyl-12-(trifluoromethyl)-2,4,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-4,7-dimethyl-12-(trifluoromethyl)-2,5,8,13-tetrazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-*N*-(2-hydroxyethyl)-7-methyl-12-(trifluoromethyl)-2,5,8,13-tetrazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene-4-carboxamide;

(10*S*)-6-chloro-8-(2,6-difluorophenyl)-10-methyl-5-(trifluoromethyl)-1,4,9,12-tetrazatetracyclo[9.6.0.02,7.013,17]heptadeca-2(7),3,5,8,11,13(17)-hexaene;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-*N*-(2-hydroxy-2-methyl-propyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene-4-carboxamide;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-*N*-[(1-hydroxycyclopropyl)methyl]-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene-4-carboxamide;

(7S)-11-chloro-9-(2,6-difluorophenyl)-*N*-*cis*-(3-hydroxycyclobutyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene-4-carboxamide; and

(7S)-11-chloro-9-(2,6-difluorophenyl)-*N*-*trans*-(3-hydroxycyclobutyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene-4-carboxamide.

13. The compound of formula (I) according to claim 12, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is selected from:

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-3,7-dimethyl-12-(trifluoromethyl)-2,4,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene;

[(7*S*)-11-chloro-9-(2,6-difluorophenyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaen-4-yl]-(3-hydroxy-3-methyl-azetidin-1-yl)methanone;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-*N*-[(2*S*)-2-hydroxypropyl]-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene-4-carboxamide;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-*N*-(2-hydroxyethyl)-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene-4-carboxamide;

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-*N*-[(2*R*)-2-hydroxypropyl]-7-methyl-12-(trifluoromethyl)-2,3,5,8,13-pentazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene-4-carboxamide; and

(7*S*)-11-chloro-9-(2,6-difluorophenyl)-*N*-(2-hydroxyethyl)-7-methyl-12-(trifluoromethyl)-2,5,8,13-tetrazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,8,11,13-hexaene-4-carboxamide.

14. A compound of formula (I) according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.

15. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.

16. A method for treating or preventing acute neurological disorders, chronic neurological disorders and/or cognitive disorders in a subject, said method comprising administering an effective amount of a compound of formula (I) according to any of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 15, to the subject.

17. Use of a compound of formula (I) according to any of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 15, in a method according to claim 16.

18. A compound of formula (I) according to any of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 15, for use in a method according to claim 16.

19. Use of a compound of formula (I) according to any of claims 1 to 13, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.

20. The method according to claim 16, the uses according to claims 17 and 19, and the compound, pharmaceutically acceptable salt thereof, or pharmaceutical composition for use according to claim 18, wherein said acute neurological disorders, chronic neurological disorders and/or cognitive disorders are selected from autism spectrum disorders (ASD), Angelman syndrome, age-related cognitive decline, Rett syndrome, Prader-Willi syndrome, amyotrophic lateral sclerosis (ALS), fragile-X disorder, negative and/or cognitive symptoms associated with schizophrenia, tardive dyskinesia, anxiety, social anxiety disorder (social phobia), panic disorder, agoraphobia, generalized anxiety disorder, disruptive, impulse-control and conduct disorders, Tourette's syndrome (TS), obsessive-compulsive disorder (OCD), acute stress disorder, post-traumatic stress disorder (PTSD), attention deficit hyperactivity disorder (ADHD), sleep disorders, Parkinson's disease (PD), Huntington's chorea, Alzheimer's disease (AD), mild cognitive impairment (MCI), dementia, behavioral and psychological symptoms (BPS) in neurodegenerative conditions, multi-infarct

dementia, agitation, psychosis, substance-induced psychotic disorder, aggression, eating disorders, depression, chronic apathy, anhedonia, chronic fatigue, seasonal affective disorder, postpartum depression, drowsiness, sexual dysfunction, bipolar disorders, epilepsy and pain.

5